Headache Archive

Ask the doctor

Q. I read that the death rate from COVID-19 is going down, but that people who recover from the infection still can remain sick for a long time. Is that true?

A. It is true, but we don't yet know how big the problem is: COVID-19 has been with us for only a year, and there hasn't been enough time to know the long-term effects.

Millions of people suffer from migraines, and research has been trying to understand what causes them. A current theory involves branches of the trigeminal nerve. Now the FDA has cleared an over-the-counter device to prevent or treat migraine by stimulating this nerve with mild electrical shocks.

Research we're watching

People with chronic pain may be more likely to have a heart attack or stroke than those without chronic pain, according to a study published online May 7, 2020, by the journal Pain Medicine.

From 2001 to 2005, researchers identified 17,614 Taiwanese people who had used pain relievers for at least three months. The most common causes of pain were spinal disorders, arthritis, and headaches; the pain relievers included both over-the-counter drugs and prescription opioids. For the comparison group, researchers used 35,228 people without chronic pain who were matched by age and sex to those in the first group.

Headaches have many possible causes, and proper management requires accurate diagnosis. Someone with increasingly severe headaches would want to have a brain imaging test to determine the underlying causes, but such tests are more effective in certain situations than others.

There are several common triggers for headaches. Identifying the one that is causing your headache is the first step toward avoiding it or ensuring you can treat it properly.

A sense of dizziness or spinning associated with migraine headache is called vestibular migraine. A small study found that a type of nerve stimulation treatment improved symptoms of vestibular migraine in study participants.

Research we're watching

If you suffer from migraine headaches, there's a new option available to relieve your pain. In October 2019, the FDA approved lasmiditan (Reyvow) to treat migraine pain in adults. Taken as a pill, it works for migraines either with or without an aura (a visual disturbance within the hour before migraine pain starts). Lasmiditan is not designed to prevent migraines. Lasmiditan is the first migraine treatment in a class of drugs known as serotonin (5-HT) 1F receptor agonists. In studies, researchers found that it could relieve pain and other migraine symptoms within two hours.

Migraines affect an estimated 28 million women in the United States, according to the American Migraine Foundation, and the World Health Organization ranks them among the top 10 disabling conditions. Pain and other symptoms, which may include nausea, sensitivity to light and temporary vision changes, result in lost work days, reduced productivity, and diminished quality of life for many people.